Hershey links gum sales to Ozempic

Candy companies usually worry that GLP-1 drugs will make people eat less sugar. Hershey just showed the other side of that trade. On April 30, during its first-quarter 2026 results, CEO Kirk Tanner said the company is seeing strong demand for gum and mints as the category benefits from “functional snacking” tailwinds, including GLP-1 adoption. The striking part was the implication — some people taking Ozempic- and Wegovy-type drugs seem to be buying breath fresheners to deal with nausea, dry mouth, burping, or what social media has started calling “Ozempic breath.” ### What actually changed? The news was not a drug approval or a medical study. It was a consumer company saying out loud that GLP-1 use is already affecting what people buy in the checkout aisle. Hershey reported first-quarter net sales of $3.10 billion, up 10.6%, and Tanner singled out gum and mints as a pocket of strength inside that bigger result. ### What did Hershey say? The most concrete number was Ice Breakers. Tanner said retail sales for Hershey’s third-largest confection brand increased more than 8% in the quarter. He framed that as part of a broader “functional snacking” trend — basically, people are not just buying treats for indulgence, they are buying products that solve a small problem in the moment. In this case, the problem is breath or mouth feel. ### Why would GLP-1 drugs affect breath? The direct phrase “Ozempic breath” is not an official diagnosis. But the mechanism is pretty plausible. Semaglutide labels list nausea, vomiting, diarrhea, reflux-related symptoms, and burping among gastrointestinal side effects, especially during dose escalation. Slower digestion and eating less can also make things worse — saliva is basically the mouth’s rinse cycle. ### Is bad breath an official side effect? Not in the neat, branded way social media talks about it. You will not usually see “Ozempic breath” listed as a formal adverse event term. What you do see are the ingredients around it — nausea, vomiting, eructation, reflux, appetite changes, and reduced oral moisture. So Hershey is making an inference from real consumer behavior, not citing a settled medical category. ### Why is this such a big deal for Hershey? Because GLP-1s were supposed to be bad news for snack makers. If millions of people eat less, candy and salty snacks look vulnerable. Hershey is now arguing that at least one part of its portfolio may benefit instead. Ice Breakers gives the company a hedge — if appetite-suppressing drugs cut some impulse snacking, breath fresheners and gum may pick up some of that lost traffic. ### Is this just a weird one-off? Maybe not. The interesting thing is not just gum. It is the idea that GLP-1 adoption is reshaping everyday consumer categories in small, specific ways. Products tied to hydration, protein, digestive comfort, smaller portions, and oral care could all see similar knock-on effects. Hershey just became one of the first big packaged-goods companies to say that plainly. ### So what’s the bottom line? This story is really about second-order effects. GLP-1 drugs are not only changing waistlines and food spending — they are starting to change the mix of products people reach for. Hershey’s 8% Ice Breakers jump will not prove “Ozempic breath” as a medical phenomenon on its own. But it does show that one of the biggest names in candy thinks the behavior is real enough to show up in sales.